Erratum: IL-12 gene-modified bone marrow cell therapy suppresses the development of experimental metastatic prostate cancer

Correction to: Cancer Gene Therapy (2007) 14, 819–827; e-pub ahead of print 13 July 2007; doi:10.1038/sj.cgt.7701069

In the above article, the authors have found an error in Figure 1.

Figure 1

Anti-metastatic effect of DFG-mIL-12-transduced BMC. Retroviral vector-transduced 129/Sv Rosa BMC (10⁶) were injected via the tail vein into recipient 129/Sv male mice without prior bone marrow ablation 3 days following tumor cell injection. The experimental scheme is shown in (a). Serum IL-12 level was monitored by ELISA (p70/p40) at 3-day intervals following retroviral vector-transduced BMC treatment (MOI=2) (b). At day 21 after treatment, lungs were removed and fixed in Bouin's solution. Formation of lung metastatic colonies was quantified in (c). Femurs were fixed and stained with H&E. Formation of bone metastasis at low and high magnification in mice treated with DFG-eGFP-transduced BMC (d and e, respectively), and in mice treated with DFG-mIL-12-transduced BMC (f and g, respectively). Data are representative of three mice per group per experiment of two independently performed experiments. H&E, hematoxylin and eosin stain.

The correct P-values that are stated in the Results section are P=0.0036 (comparing DFG-mIL-12 with HBSS) and P=0.0197 (comparing DFG-mIL-12 with DFG-eGFP).

The correct figure is shown below.

The authors would like to apologize for this mistake.